This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Congenital dyserythropoietic anaemia, CDA선천성 적혈구조혈이상빈혈

ICD-10: D64.4 | Synonyms: CDA, Congenital dyserythropoietic anaemia, congenital ineffective erythropoiesis anemia

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

Early descriptions

Congenital dyserythropoietic anemia (CDA) was first described as an independent disease entity by Wendt and Heimpel in 1966. They classified anemic patients showing distinctive dysplastic findings in the bone marrow, such as multinuclear erythroblasts and internuclear chromatin bridges, and named this "congenital dyserythropoietic anemia."

Establishment of a subtype classification system

In 1968, Heimpel and Wendt proposed a system classifying CDA into types I, II, and III based on bone marrow morphological features and serological findings. This classification system is still used as the foundation of CDA diagnosis. Additional subtypes (CDA type IV, CDA type X, etc.) were later described with advances in molecular genetic techniques.

Elucidation of the molecular basis

In 2002, CDAN1 (codanin-1) was identified as the causative gene of CDA type I, and in 2009 SEC23B was identified as the causative gene of CDA type II, revealing that a defect in the COPII vesicle transport protein causes impaired red cell maturation.

Status in Korea

In Korea, CDA is a very rare disease, published in the form of individual case reports. Most are diagnosed as type I or type II, and accurate molecular genetic diagnosis is gradually becoming possible.

2. Causes

Causes of CDA type I

The most common cause of CDA type I is variants in the CDAN1 gene (15q15.2, autosomal recessive). CDAN1 encodes the codanin-1 protein, which functions as a histone chaperone (interacting with CHAF1B) and in DNA replication. Variants in the C15ORF41 gene also cause CDA type I.

Causes of CDA type II

CDA type II (HEMPAS) is caused by variants in the SEC23B gene (20p11.21, autosomal recessive). SEC23B is a component of the COPII vesicle coat complex and is involved in protein transport from the endoplasmic reticulum to the Golgi apparatus. Loss of SEC23B function causes abnormal glycosylation of red cell membrane glycoproteins.

CDA type III and other causes

CDA type III is caused by KIF23 gene variants (autosomal dominant), and dysfunction of the MKLP-1 (kinesin family member 23) protein leads to formation of multinucleated giant erythroblasts. Other reported causative genes are KLF1/EKLF (CDA type IV, autosomal dominant) and GATA1 (CDAX, X-linked).

3. Genetics

Inheritance pattern by subtype

SubtypeCausative geneChromosomal locationMode of inheritance
CDA type ICDAN1, C15ORF4115q15.2Autosomal recessive
CDA type II (HEMPAS)SEC23B20p11.21Autosomal recessive
CDA type IIIKIF2315q23Autosomal dominant
CDA type IVKLF1/EKLF19p13.2Autosomal dominant
CDAXGATA1Xp11.23X-linked

Founder effect

The CDAN1 p.R1042W variant in CDA type I shows a high carrier frequency among Ashkenazi Jews due to a founder effect. The SEC23B p.E109K variant in CDA type II is frequently reported in southern Italy due to a founder effect.

Phenotypic heterogeneity

Clinical severity varies even with the same gene variant, reflecting additional gene variants (modifier genes), environmental factors, and genotype-phenotype complexity. In the case of SEC23B, severity differs greatly by variant type.

4. General epidemiology

Worldwide prevalence

CDA is an extremely rare disease; an estimated fewer than about 500–1,000 patients are registered worldwide. The exact prevalence is likely underestimated because of diagnostic difficulty.

Frequency by subtype

CDA type II is the most common, accounting for 60–70% of all CDA. The frequency of CDA type II is relatively high in Mediterranean regions such as Italy and Spain. CDA type I accounts for 20–30% of the total and is frequent among Ashkenazi Jews. CDA type III is very rare, and a high-frequency kindred has been reported in a rural area of northern Sweden.

Status in Korea

In Korea, separate epidemiological data on CDA are limited, and it is identified through individual case reports. It is managed within the rare disease registration system and is mainly diagnosed at tertiary hospitals capable of molecular genetic diagnosis (Seoul National University Hospital, Samsung Medical Center, etc.).

5. Pathophysiology

Ineffective erythropoiesis

The core pathogenesis of CDA is ineffective erythropoiesis. Proliferation of erythroblasts in the bone marrow is normal or increased, but because of dysplasia and abnormal cell division during maturation, most erythroblasts are abnormally destroyed within the bone marrow (intramedullary hemolysis).

Mechanism of CDA type I: chromatin abnormalities

The CDAN1 protein (codanin-1) binds to the B subunit of the histone chaperone CAF-1 (CHAF1B) and assists chromatin assembly after DNA replication. With loss of function, defects in chromatin structure formation arise in erythroblasts, causing intranuclear cavity formation ("Swiss cheese" dysplasia) and internuclear chromatin bridges.

Mechanism of CDA type II: COPII transport defect and membrane abnormalities

With SEC23B dysfunction, protein transport via COPII vesicles decreases, and red cell membrane glycoproteins (band 3, band 4.5, etc.) are abnormally glycosylated. Formation of double membranes (cisternae) in binucleated and multinucleated erythroblasts is characteristic.

Mechanism of CDA type III: abnormal cell division

KIF23 (MKLP-1) is located at the central spindle and is involved in spindle completion and initiation of cytokinesis during cell division. With dysfunction, cytokinesis cannot be completed, forming giant cells (gigantoblasts) containing up to 12 nuclei.

6. Symptoms

Symptom characteristics by subtype

Common symptoms

Fatigue, reduced exercise tolerance, pallor, and dizziness are common symptoms. Jaundice (scleral icterus) reflects increased indirect bilirubin due to ineffective erythropoiesis. Abdominal pain due to gallstones may recur.

Symptoms of iron overload

Even without transfusion, iron overload progresses slowly because of ineffective erythropoiesis. It can cause liver fibrosis, reduced cardiac function, and endocrine dysfunction (diabetes, hypothyroidism, growth delay).

7. Signs

Physical examination findings

Pallor, jaundice (including scleral icterus), splenomegaly, and hepatomegaly are the main physical findings. The skin may become yellowish-brown (iron overload). In CDA type I, finger and toe malformations (polydactyly, brachydactyly, syndactyly) may be observed.

Bone marrow findings (by subtype)

SubtypeLight microscopy findingsElectron microscopy findingsSerology
CDA type IInternuclear chromatin bridges, binucleated erythroblasts, Swiss cheese chromatinChromatin cavities, abnormal nuclear membrane–endoplasmic reticulum connectionsHam test negative
CDA type IIBinucleated to multinucleated (up to 5 nuclei) erythroblasts, frequent in polychromatophilic cellsDouble membranes (double cisternae)Ham test positive, strong i antigen expression
CDA type IIIGiant multinucleated erythroblasts with up to 12 nuclei (gigantoblasts)Failure to complete nuclear divisionGenerally normal

Blood test findings

Normocytic or macrocytic anemia; reticulocyte count inappropriately low or mildly increased; elevated indirect bilirubin, elevated LDH, decreased haptoglobin (hemolysis markers); elevated serum ferritin and serum iron (iron overload).

8. Screening

When to suspect clinically

CDA is suspected in the following situations: ① chronic anemia of unknown cause in childhood to adolescence; ② anemia with a reticulocyte count low relative to hemolysis markers; ③ anemia accompanied by splenomegaly and jaundice; ④ anemia requiring repeated transfusions with a negative family history; ⑤ similar anemia in family members.

Primary screening tests

CBC and absolute reticulocyte count; peripheral blood smear; hemolysis markers (LDH, bilirubin, haptoglobin, urobilinogen); serum ferritin and transferrin saturation.

Screening specific to CDA type II

Ham test (acidified serum hemolysis test): limited sensitivity but usable as low-cost screening. Flow cytometry (CD55/CD59, i antigen): distinguishes CDA type II from PNH.

9. Diagnosis

Morphological diagnosis by bone marrow

Bone marrow morphological examination is the core of CDA diagnosis. Subtype-specific findings are confirmed by light and electron microscopy. Internuclear chromatin bridges (CDA type I), binucleated and multinucleated erythroblasts and double membranes (CDA type II), and giant multinucleated erythroblasts (CDA type III) are identified.

Molecular genetic diagnosis

Molecular genetic testing is essential for definitive diagnosis and subtype classification of CDA. Sequencing of the CDAN1, C15ORF41 (CDA type I), SEC23B (CDA type II), KIF23 (CDA type III), KLF1 (CDA type IV), and GATA1 (CDAX) genes or NGS panel testing is performed.

Differential diagnosis

Hemoglobin electrophoresis/HPLC (to exclude thalassemia and sickle cell anemia); red cell enzyme tests (to exclude G6PD deficiency and pyruvate kinase deficiency); direct antiglobulin test (DAT, to exclude immune hemolysis); flow cytometry (to exclude PNH); cytogenetic testing and somatic variant NGS to exclude MDS.

10. Treatment

Transfusion therapy

Transfusion may not be needed in mild CDA, but packed red cell transfusion is given for moderate or greater anemia (Hb <7 g/dL) or when symptoms are present. Minimizing the number of transfusions is important for preventing iron overload.

Iron chelation therapy

Non-transfusional iron overload results from increased intestinal iron absorption due to ineffective erythropoiesis and occurs regardless of transfusion. Iron chelators such as deferoxamine, deferasirox, and deferiprone are given according to serum ferritin levels.

Interferon-alpha (specific treatment for CDA type I)

Interferon-alpha (IFN-α) treatment in CDA type I has been reported in some cases to reduce ineffective erythropoiesis and improve anemia. The response rate is about 60–70%.

Splenectomy and hematopoietic stem cell transplantation

Splenectomy is performed for increased transfusion requirements due to hypersplenism or for severe splenomegaly. In severe CDA (especially severe CDA type I), allogeneic HSCT from an HLA-matched donor is considered as a treatment option.

11. Prognosis

Prognosis by subtype

Long-term complications and survival

Reduced cardiac function, liver cirrhosis, and endocrine complications due to iron overload are the main long-term complications. Normalization of life expectancy is possible in patients receiving appropriate iron chelation therapy. With successful HSCT, a curative outcome can be expected. Blood tests every 6 months, and liver MRI T2* (quantification of iron overload), echocardiography, and endocrine function tests every 1–2 years are performed.

12. Prevention

Genetic counseling

Because CDA is a genetic disease, genetic counseling must be provided after diagnosis. For autosomal recessive types (CDA types I and II), confirmation of parental carrier status and testing of siblings are recommended. For future pregnancies, prenatal genetic testing (CVS or amniocentesis) or preimplantation genetic testing (PGT-M) is possible.

Prevention of iron overload

Increased intestinal iron absorption due to ineffective erythropoiesis should be recognized early, and iron chelation should be started before serum ferritin reaches >1,000 μg/L. Unnecessary iron supplements and excessive vitamin C intake should be avoided.

Prevention of complications

After splenectomy, vaccination against encapsulated bacteria (pneumococcus, meningococcus, Haemophilus influenzae) and prophylactic antibiotics (penicillin). Early surgical treatment when gallstones develop. Prevention of acute worsening of anemia through early treatment of infections.

13. References

  1. Heimpel H, Wendt F. Congenital dyserythropoietic anaemia with karyorrhexis and multinuclearity of erythroblasts. Helv Med Acta. 1968;34(1-2):103-115.
  2. Wickramasinghe SN, Wood WG. Advances in the understanding of congenital dyserythropoietic anaemias. Br J Haematol. 2005;131(4):431-446.
  3. Dgany O, Avidan N, Delaunay J, et al. Congenital dyserythropoietic anemia type I is caused by mutations in codanin-1. Am J Hum Genet. 2002;71(6):1467-1474.
  4. Schwarz K, Iolascon A, Verissimo F, et al. Mutations affecting the secretory COPII coat component SEC23B cause congenital dyserythropoietic anemia type II. Nat Genet. 2009;41(8):936-940.
  5. Iolascon A, Heimpel H, Wahlin A, Tamary H. Congenital dyserythropoietic anemias: molecular insights and diagnostic approach. Blood. 2013;122(13):2162-2166.
  6. Tamary H, Dgany O, Proust A, et al. Clinical and molecular variability in congenital dyserythropoietic anaemia type I. Br J Haematol. 2005;130(4):628-634.
  7. Shalev H, Kapelushnik J, Moser A, et al. A comprehensive study of the neonatal manifestations of congenital dyserythropoietic anemia type I. J Pediatr Hematol Oncol. 2004;26(11):746-748.
  8. Heimpel H, Anselstetter V, Chrobak L, et al. Congenital dyserythropoietic anemia type II: epidemiology, clinical appearance, and prognosis. Blood. 2003;102(13):4576-4581.
  9. Marwaha RK, Bansal D, Trehan A, Garewal G. Congenital dyserythropoietic anemia in a north Indian family. Pediatr Hematol Oncol. 2003;20(7):563-566.
  10. Roy NBA, Bhatt V, Bhatt VR, et al. Congenital dyserythropoietic anaemia—new insights into pathogenesis and treatment. Curr Opin Hematol. 2023;30(3):137-144.
  11. Gambale A, Iolascon A, Andolfo I, Russo R. Diagnosis and management of congenital dyserythropoietic anemias. Expert Rev Hematol. 2016;9(3):283-296.
  12. Perrotta S, Iolascon A, Rund D, et al. Treatment of congenital dyserythropoietic anemia type II. Haematologica. 2018;103(5):e178-e181.